godzilla 2014

Godzila or Godzilla OR Gojira?

The summer’s second tentpole — likely launching a new Hollywood franchise — opens to $103 million overseas for a global total of $196.2 million; Jon Hamm’s sports drama “Million Dollar Arm” muted.

Gareth Edwards’ Godzilla debuted to a monstrous $93.2 million from 3,952 theaters at the domestic box office, giving the iconic giant lizard a new lease on life and delivering the second-best opening of the year.

Overseas, the $160 million movie debuted to $103 million from 64 markets for a global total of $196.2 million for Legendary Pictures and Warner Bros.
PHOTOS: ‘Godzilla’ Premiere Invades L.A.
Godzilla was so strong on Friday in North America that some box office observers believed it could approach $98 million for the weekend. Either way, the movie’s debut far exceeded expectations. Males fueled the film (58 percent), and especially younger males, a demo that is harder and harder to lure to the multiplex.
Overall, 40 percent of ticket buyers were under the age of 40. While Godzilla received a B+ CinemaScore overall, the younger demo gave it an A CinemaScore.
Marking the summer’s second tentpole, Godzilla delivered the second-best opening of the year so far after Captain America: The Winter Soldier ($95 million) and bested the $91.6 million opening of The Amazing Spider-Man 2 two weeks ago.
The $160 million movie did especially strong business in fanboy friendly Imax theaters, which turned in 15 percent of the overall gross with $13.5 million from 352 locations, putting the theater average at a stellar $40,057. And more than half of the movie’s earnings came from 3D locations, an especially strong showing.
Godzilla, finally launching a Hollywood studio franchise headlined by the giant lizard, is a defining moment for Legendary Pictures, which spearheaded the reboot. Thomas Tull’s Legendary financed 75 percent of Godzilla, with Warner Bros. putting up the rest of the money.

read more at: http://www.hollywoodreporter.com/news/box-office-godzilla-opens-monstrous-705168

CHOLESTEROL

New Drug May Help Lower ‘Bad’ Cholesterol Beyond Statins

TUESDAY, May 13, 2014 (HealthDay News) — A new injectable drug can further knock down cholesterol levels in people who take cholesterol-busting statin medications, according to the results of a global trial.

People taking the new therapy alongside statins enjoyed a 63 percent to 75 percent decrease in their “bad” (LDL) cholesterol levels, on top of the reduction caused by the traditional statin medications, researchers reported. The findings are published in the May 14 issue of the Journal of the American Medical Association.

“This drug enhances the body’s natural way of reducing LDL levels in the bloodstream,” said lead author Dr. Jennifer Robinson, a professor of epidemiology and cardiology at the University of Iowa College of Public Health. “It lets us get cholesterol really well-treated in people with genetic cholesterol disorders or people who can’t take large amounts of statins.”

Evolocumab is a so-called “human monoclonal antibody” that, in a roundabout way, improves the body’s ability to remove cholesterol from the bloodstream.

Cells primarily located in the liver contain receptors that target LDL cholesterol and remove it from the bloodstream. But the liver also produces a regulatory protein called PCSK9 that binds to and breaks down these receptors, Robinson said.

The antibodies in evolocumab are designed to intercept PCSK9, preventing the protein from breaking down the cells’ LDL receptors, which allows them to stay in circulation longer to remove LDL cholesterol, she explained.

The phase 3 clinical trial was funded by the drug’s maker, Amgen, and conducted at 198 sites in 17 countries. Over the course of 12 weeks, just over 2,000 people taking moderate to high doses of statins were randomly assigned to also take evolocumab, or another cholesterol-lowering drug called ezetimibe (Zetia), or an inactive placebo.

Compared with the placebo, evolocumab taken every two weeks reduced LDL cholesterol levels an additional 66 percent to 75 percent, and taken monthly cut the level by 63 percent to 75 percent. By comparison, ezetimibe provided an additional cholesterol reduction of up to 24 percent, the investigators found.

full news at here